newsfilter
← Latest News
ACCESS Newswire·

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

TELO
  • Telomir Pharmaceuticals announced preclinical results showing Telomir-1 reactivates tumor suppressor genes MASPIN & RASSF1A by reversing their abnormal DNA methylation in aggressive prostate cancer models.
  • Restored MASPIN activity blocks tumor invasion, regulates cell migration, promotes apoptosis, & enhances sensitivity to chemotherapy.
  • Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects observed when combined with chemotherapy.
  • The therapy demonstrates the ability to counteract chemotherapy-induced resistance mechanisms & limit metastasis, which accounts for most cancer deaths.
  • Dr. Itzchak Angel noted the significance of Telomir-1 resetting DNA methylation to restore silenced tumor suppressors & address cancer at its epigenetic roots.
  • CEO Erez Aminov stated the findings suggest a new era in medicine where underlying epigenetic programs driving tumor growth & cellular decline are reset.
  • Prior preclinical data indicates Telomir-1 reactivates other suppressors like STAT1 & CDKN2A while inhibiting previously undruggable histone demethylases.
  • The therapy showed functional outcomes including ~50% tumor volume reduction & elimination of chemotherapy-related mortality in aggressive prostate cancer models.
  • Telomir-1 also demonstrated potential benefits for aging by elongating telomeres & reversing epigenetic drift in accelerated-aging models.
  • Telomir is advancing Telomir-1 through IND-enabling studies with additional evaluations planned for prostate cancer & other aggressive tumor models.